Skip to main content
. 2021 May 31;19(2):313–322. doi: 10.9758/cpn.2021.19.2.313

Table 3.

Comparison of each spectral power between each antipsychotic drug group and drug-free patients

Lead F3 F4 C3 C4 P3 P4 O1 O2
Free
Delta 53.6 ± 2.7 53.6 ± 2.5 51.8 ± 2.4 52.0 ± 2.5 51.4 ± 2.4 51.7 ± 2.4 51.7 ± 2.8 51.7 ± 2.8
Theta 48.1 ± 2.6 48.3 ± 2.4 47.4 ± 2.6 47.4 ± 2.7 47.2 ± 2.7 47.4 ± 2.7 47.3 ± 3.2 47.3 ± 3.3
Alpha 46.8 ± 2.4 46.9 ± 2.4 46.7 ± 2.4 46.9 ± 2.5 47.9 ± 3.1 48.2 ± 3.0 49.2 ± 3.8 49.2 ± 3.9
Beta 41.2 ± 2.5 41.5 ± 2.6 40.8 ± 2.3 41.1 ± 2.3 40.8 ± 2.2 41.1 ± 2.2 41.2 ± 2.4 41.2 ± 2.5
Gamma 34.0 ± 6.3 34.2 ± 5.9 33.4 ± 6.2 33.0 ± 5.4 32.0 ± 4.2 32.0 ± 4.2 32.4 ± 3.7 32.3 ± 3.9
ARP
Delta 52.9 ± 2.2 52.9 ± 1.9 52.2 ± 2.0 52.7 ± 2.0 52.8 ± 2.0 53.2 ± 2.0 53.8 ± 3.0 53.4 ± 2.5
Theta 50.0 ± 2.6 50.2 ± 2.6 49.8 ± 2.6 50.2 ± 2.9 50.0 ± 2.8 50.2 ± 3.1 50.6 ± 3.4 50.3 ± 3.7
Alpha 49.3 ± 3.4 49.4 ± 3.2 49.4 ± 3.2 49.7 ± 3.2 50.5 ± 3.6 50.4 ± 3.8 52.3 ± 4.7 52.0 ± 5.1
Beta 41.1 ± 1.7 41.2 ± 1.7 40.9 ± 1.6 41.2 ± 1.8 41.2 ± 2.0 41.4 ± 2.0 42.1 ± 3.0 41.9 ± 3.3
Gamma 29.9 ± 3.8 31.2 ± 3.9 29.1 ± 3.2 29.6 ± 3.6 29.0 ± 2.8 29.1 ± 3.1 29.5 ± 2.9 29.8 ± 3.4
RIS
Delta 51.5 ± 2.7 51.4 ± 2.2 50.4 ± 1.4 50.4 ± 1.0 50.1 ± 1.0 50.4 ± 1.2 50.1 ± 1.8 50.5 ± 2.3
Theta 49.4 ± 1.5 49.2 ± 1.4 49.2 ± 1.4 49.0 ± 1.3 49.0 ± 1.6 49.1 ± 1.5 48.7 ± 2.2 49.6 ± 2.6
Alpha 49.6 ± 2.4 49.7 ± 2.5 50.3 ± 2.5* 50.6 ± 2.6* 51.6 ± 2.5 51.8 ± 2.7 52.1 ± 3.0 52.9 ± 3.1
Beta 43.9 ± 2.6 44.0 ± 2.7 44.1 ± 2.1* 44.7 ± 2.4* 44.2 ± 2.3* 44.3 ± 2.2* 43.5 ± 2.6 43.9 ± 2.6
Gamma 35.2 ± 3.7 35.4 ± 5.3 33.3 ± 3.9 35.7 ± 6.1 32.7 ± 2.9 33.6 ± 3.8 33.4 ± 2.7 33.7 ± 3.0
CLZ
Delta 55.7 ± 1.9 55.1 ± 2.5 54.2 ± 1.5 53.9 ± 1.6 54.0 ± 1.9 54.1 ± 2.2 52.1 ± 3.2 52.0 ± 2.9
Theta 53.9 ± 2.6 53.6 ± 3.0 52.7 ± 2.8 52.9 ± 2.9* 51.7 ± 2.6* 52.1 ± 3.1* 49.9 ± 3.2 49.1 ± 4.1
Alpha 48.2 ± 1.9 47.9 ± 1.3 47.8 ± 1.4 48.0 ± 1.2 48.1 ± 1.2 47.8 ± 1.2 47.3 ± 1.8 46.1 ± 1.9
Beta 39.5 ± 3.4 39.6 ± 2.7 39.4 ± 2.8 39.8 ± 2.5 39.2 ± 2.2 39.4 ± 2.0 38.8 ± 2.0 38.9 ± 2.0
Gamma 27.3 ± 2.9 27.5 ± 2.3 27.0 ± 2.6 26.9 ± 2.1 28.3 ± 2.9 27.8 ± 2.2 29.1 ± 3.4 30.8 ± 4.0
OLZ
Delta 59.1 ± 4.2 58.8 ± 3.8 56.8 ± 4.5 57.0 ± 4.3 56.8 ± 3.9* 57.0 ± 3.5* 56.7 ± 4.7 57.0 ± 5.0
Theta 53.0 ± 3.4 52.5 ± 3.2 51.6 ± 2.5 51.4 ± 2.9 51.0 ± 3.2 51.0 ± 3.2 50.6 ± 3.8 50.4 ± 4.1
Alpha 50.3 ± 4.9 50.2 ± 4.5 50.0 ± 3.8 50.0 ± 3.9 50.6 ± 5.5 50.3 ± 5.1 51.2 ± 6.1 51.1 ± 6.6
Beta 44.7 ± 3.6 44.8 ± 3.5 44.6 ± 3.5 44.3 ± 3.2 44.5 ± 3.8 44.2 ± 3.7 44.9 ± 3.6 45.1 ± 3.9
Gamma 37.0 ± 4.5 36.1 ± 4.8 35.2 ± 6.2 34.0 ± 6.4 34.0 ± 3.9 33.8 ± 4.2 35.3 ± 3.8 36.0 ± 3.8
BNS
Delta 55.4 ± 3.9 55.3 ± 4.5 53.6 ± 5.0 53.4 ± 5.0 53.7 ± 3.8 53.9 ± 4.4 54.3 ± 5.9 53.7 ± 5.2
Theta 50.4 ± 3.5 50.6 ± 3.4 49.7 ± 3.9 49.6 ± 3.6 49.5 ± 3.8 49.6 ± 4.1 49.6 ± 5.6 49.3 ± 5.3
Alpha 49.1 ± 2.7 49.3 ± 3.0 49.4 ± 2.8 49.2 ± 2.7 51.3 ± 3.7 50.8 ± 3.6 53.9 ± 5.5 53.0 ± 5.1
Beta 42.0 ± 2.7 42.0 ± 2.7 42.2 ± 2.7 42.0 ± 2.9 43.5 ± 2.9 42.9 ± 3.0 44.7 ± 4.4 44.5 ± 3.9
Gamma 33.6 ± 1.9 32.4 ± 1.3 32.1 ± 1.2 31.8 ± 1.4 32.4 ± 2.0 31.9 ± 1.9 34.4 ± 2.7 33.9 ± 2.9

Each value represents the mean regional absolute power in mV2 ± standard deviation.

Free: drug-free patients. ARP, aripiprazole; RIS, risperidone; CLZ, clozapine; OLZ, olanzapine; BNS, blonanserin.

pvalue represents the significance of differences in spectral power between drug-free patients and each antipsychotic drug group (*p < 0.05). A Mann−Whitney Utest with a Dunn correction were used to adjust the pvalues for multiple comparisons.